# About CJC-1295 Ipamorelin: An Independent Editorial Digest

> About this CJC-1295 Ipamorelin editorial project: an independent publisher of plain-English summaries of the peer-reviewed research. Not a clinic, not a vendor, not medical advice.

An independent editorial reading of the literature — careful, cited, and clear about what it is.

## What Rx CJC-Ipa is

Rx CJC-Ipa is an independent editorial project that publishes summaries of the peer-reviewed research literature on CJC-1295 Ipamorelin — the two-peptide growth-hormone-secretagogue combination of a long-acting GHRH analogue and a selective ghrelin-receptor agonist. We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

Every quantitative claim on this site is tied to a specific study in the references list, and the central honesty of the project is stated plainly throughout: neither peptide is FDA-approved, and the fixed combination has never been tested in a controlled clinical trial.

## About the "rx" in the name

The "rx" in this domain's name is editorial framing — a position this publisher takes relative to the literature, the way a column or a reading room occupies a stance — not a claim about services. This site is not a pharmacy, dispenses nothing, and offers no prescription, consultation, or treatment. We chose the controversies-and-availability angle precisely because the "rx" query tends to attract hype and vendor stand-ins; the corrective is a sober, cited record of what the research does and does not show. The framing is a lens on the science, not an offer of access to a drug.

## How we handle the evidence

We lead with what was measured and attribute it to the study that measured it. We distinguish CJC-1295 with DAC from the no-DAC Mod GRF (1-29) form, because they have entirely different durations of action and conflating them is the single most common error in this space. We report doses only as they appear in research — by species and route — and never as instructions. Where the evidence is strong, we say so; where it is thin or missing, we say that too, including the central fact that the combination itself has never been trialed. We use only generic peptide names and avoid drug brand names entirely.

---

A cool-pressed editorial reading of the CJC-1295 and ipamorelin literature, set in ruled columns — the mechanism, the with-DAC and no-DAC clocks, and the combination trial that was never run, each line cited; no clinic behind the masthead and nothing here dosed, prescribed, or sold.